Addex Therapeutics Ltd. SEC filings ADXN
Addex Therapeutics Ltd. has 279 filings in SEC EDGAR's recent list, going back to Sep 24, 2019. Its latest annual report, Form 20-F, was filed on May 15, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Oct 29, 2026. The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| NT 20-F | Filing | Apr 30, 2026 | Dec 31, 2025 |
| EFFECT | Filing | Dec 5, 2025 | — |
| CORRESP | Letter to the SEC | Dec 3, 2025 | — |
| NT 20-F | Filing | Apr 30, 2025 | Dec 31, 2024 |
| EFFECT | Filing | Apr 22, 2024 | — |
| EFFECT | Filing | Nov 29, 2023 | — |
| EFFECT | Filing | Aug 10, 2023 | — |
| EFFECT | Filing | Jun 2, 2023 | — |
| CORRESP | Letter to the SEC | Jun 1, 2023 | — |
| CORRESP | Letter to the SEC | May 12, 2023 | — |
| CORRESP | Letter to the SEC | May 11, 2023 | — |
| UPLOAD | Letter from the SEC | May 9, 2023 | — |
| D | Filing | Apr 13, 2023 | — |
| EFFECT | Filing | Aug 29, 2022 | — |
| EFFECT | Filing | Aug 29, 2022 | — |
| CORRESP | Letter to the SEC | Aug 25, 2022 | — |
| UPLOAD | Letter from the SEC | Aug 25, 2022 | — |
| D | Filing | Aug 4, 2022 | — |
| EFFECT | Filing | Apr 19, 2022 | — |
| EFFECT | Filing | Apr 4, 2022 | — |
| CORRESP | Letter to the SEC | Mar 29, 2022 | — |
| EFFECT | Filing | Jan 18, 2022 | — |
| CORRESP | Letter to the SEC | Jan 14, 2022 | — |
| UPLOAD | Letter from the SEC | Jan 14, 2022 | — |
| D | Filing | Dec 21, 2021 | — |
| EFFECT | Filing | Apr 13, 2021 | — |
| CORRESP | Letter to the SEC | Apr 12, 2021 | — |
| UPLOAD | Letter from the SEC | Apr 9, 2021 | — |
| UPLOAD | Letter from the SEC | Feb 1, 2021 | — |
| EFFECT | Filing | Jan 6, 2021 | — |
| CORRESP | Letter to the SEC | Jan 6, 2021 | — |
| CORRESP | Letter to the SEC | Jan 5, 2021 | — |
| DEL AM | Filing | Dec 14, 2020 | — |
| UPLOAD | Letter from the SEC | Oct 15, 2020 | — |
| DRS | Filing | Oct 13, 2020 | — |
| UPLOAD | Letter from the SEC | May 11, 2020 | — |
| CERT | Filing | Jan 28, 2020 | — |
| EFFECT | Filing | Jan 27, 2020 | — |
| EFFECT | Filing | Jan 27, 2020 | — |
| CORRESP | Letter to the SEC | Jan 23, 2020 | — |
| CORRESP | Letter to the SEC | Jan 23, 2020 | — |
| UPLOAD | Letter from the SEC | Jan 15, 2020 | — |
| 8-A12B | Filing | Jan 14, 2020 | — |
| CORRESP | Letter to the SEC | Jan 13, 2020 | — |
| UPLOAD | Letter from the SEC | Dec 31, 2019 | — |
| CORRESP | Letter to the SEC | Dec 17, 2019 | — |
| SEC STAFF LETTER | Filing | Dec 16, 2019 | — |
| UPLOAD | Letter from the SEC | Dec 12, 2019 | — |
| DRSLTR | Filing | Nov 27, 2019 | — |
| DRS/A | Filing | Nov 27, 2019 | — |
| UPLOAD | Letter from the SEC | Oct 24, 2019 | — |
| SEC STAFF LETTER | Filing | Sep 26, 2019 | — |
| DRS | Filing | Sep 24, 2019 | — |
Showing 53 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ADXN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Switzerland
- Headquarters
- Geneva, Switzerland
- SEC filer status
- Non-accelerated filer
- SEC CIK
- 1574232
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.